Skip to main content
Top
Published in: BMC Infectious Diseases 1/2022

Open Access 01-12-2022 | SARS-CoV-2 | Research

Point prevalence of SARS-CoV-2 infection in Sweden at six time points during 2020

Authors: Ramona Groenheit, Jessica Beser, Sharon Kühlmann Berenzon, Ilias Galanis, Edward van Straten, Jan Duracz, Marie Rapp, Disa Hansson, Mikael Mansjö, Sandra Söderholm, Shaman Muradrasoli, Anna Risberg, Richard Ölund, Andreas Wiklund, Kristoffer Metzkes, Matilda Lundberg, Philip Bacchus, Karin Tegmark Wisell, Andreas Bråve

Published in: BMC Infectious Diseases | Issue 1/2022

Login to get access

Abstract

Background

In order to estimate the prevalence and understand the spread of SARS-CoV-2 in Sweden, the Public Health Agency of Sweden, with support from the Swedish Armed Forces, conducted a series of point prevalence surveys between March and December 2020.

Methods

Sampling material and instructions on how to perform self-sampling of the upper respiratory tract were delivered to the homes of the participants. Samples were analysed by real-time PCR, and the participants completed questionnaires regarding symptoms.

Findings

The first survey in the Stockholm region in March 2020 included 707 participants and showed a SARS-CoV-2 prevalence of 2.5%. The following five surveys, performed on a national level, with between 2461 and 2983 participants, showed SARS-CoV-2 prevalences of 0.9% (April), 0.3% (May), 0.0% (August), 0.0% (September), and 0.7% (December). All positive cases who responded to questionnaires reported experiencing symptoms that occurred from 2 weeks before the date of sampling up to and including the date of sampling.

Interpretation

None of the individuals shown to be PCR-positive were asymptomatic at the time of sampling or in the 14 days prior to sampling. This is in contrast to many other surveys in which a substantial proportion of positive cases have been reported to be asymptomatic. Our surveys demonstrate a decreasing ratio between notified cases and the observed prevalence throughout the year, in line with increasing testing capacity and the consecutive inclusion of all symptomatic individuals in the case definition for testing.
Appendix
Available only for authorised users
Literature
14.
go back to reference R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna Austria,2019. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna Austria,2019.
15.
go back to reference Lumley T. Survey: analysis of complex survey samples. R package version 4.0. 2020. Lumley T. Survey: analysis of complex survey samples. R package version 4.0. 2020.
17.
go back to reference Byambasuren O, Cardona M, Bell K, Clark J, McLaws M-L, Glasziou P. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis. medRxiv. 2020;10:40. Byambasuren O, Cardona M, Bell K, Clark J, McLaws M-L, Glasziou P. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis. medRxiv. 2020;10:40.
18.
go back to reference Adorni F, Prinelli F, Bianchi F, Giacomelli A, Pagani G, Bernacchia D, et al. Self-reported symptoms of SARS-CoV-2 infection in a non-hospitalized population: results from the large Italian web-based EPICOVID19 cross-sectional survey. JMIR Public Health Surveill. 2020. Adorni F, Prinelli F, Bianchi F, Giacomelli A, Pagani G, Bernacchia D, et al. Self-reported symptoms of SARS-CoV-2 infection in a non-hospitalized population: results from the large Italian web-based EPICOVID19 cross-sectional survey. JMIR Public Health Surveill. 2020.
19.
go back to reference Gudbjartsson DF, Helgason A, Jonsson H, Magnusson OT, Melsted P, Norddahl GL, et al. Spread of SARS-CoV-2 in the Icelandic population. N Engl J Med. 2020;382(24):2302–15.CrossRefPubMed Gudbjartsson DF, Helgason A, Jonsson H, Magnusson OT, Melsted P, Norddahl GL, et al. Spread of SARS-CoV-2 in the Icelandic population. N Engl J Med. 2020;382(24):2302–15.CrossRefPubMed
20.
go back to reference Lavezzo E, Franchin E, Ciavarella C, Cuomo-Dannenburg G, Barzon L, Del Vecchio C, et al. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo’. Nature. 2020;584(7821):425–9.CrossRefPubMed Lavezzo E, Franchin E, Ciavarella C, Cuomo-Dannenburg G, Barzon L, Del Vecchio C, et al. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo’. Nature. 2020;584(7821):425–9.CrossRefPubMed
21.
go back to reference Menachemi NYC, Dixon BE, et al. Population point prevalence of SARS-CoV-2 infection based on a statewide random sample—Indiana, April 25–29, 2020. MMWR Morb Mortal Wkly Rep. 2020;2020(69):960–4.CrossRef Menachemi NYC, Dixon BE, et al. Population point prevalence of SARS-CoV-2 infection based on a statewide random sample—Indiana, April 25–29, 2020. MMWR Morb Mortal Wkly Rep. 2020;2020(69):960–4.CrossRef
23.
go back to reference Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung SM, Hayashi K, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis. 2020;94:154–5.CrossRefPubMedPubMedCentral Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung SM, Hayashi K, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis. 2020;94:154–5.CrossRefPubMedPubMedCentral
24.
go back to reference Oran DP, Topol EJ. The proportion of SARS-CoV-2 infections that are asymptomatic. Ann Intern Med. 2021;174:655–62.CrossRefPubMed Oran DP, Topol EJ. The proportion of SARS-CoV-2 infections that are asymptomatic. Ann Intern Med. 2021;174:655–62.CrossRefPubMed
25.
go back to reference Yanes-Lane M, Winters N, Fregonese F, Bastos M, Perlman-Arrow S, Campbell JR, et al. Proportion of asymptomatic infection among COVID-19 positive persons and their transmission potential: a systematic review and meta-analysis. PLoS ONE. 2020;15(11): e0241536.CrossRefPubMedPubMedCentral Yanes-Lane M, Winters N, Fregonese F, Bastos M, Perlman-Arrow S, Campbell JR, et al. Proportion of asymptomatic infection among COVID-19 positive persons and their transmission potential: a systematic review and meta-analysis. PLoS ONE. 2020;15(11): e0241536.CrossRefPubMedPubMedCentral
26.
go back to reference Pouwels KB, House T, Pritchard E, Robotham JV, Birrell PJ, Gelman A, et al. Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey. Lancet Public Health. 2021;6(1):e30–8.CrossRefPubMed Pouwels KB, House T, Pritchard E, Robotham JV, Birrell PJ, Gelman A, et al. Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey. Lancet Public Health. 2021;6(1):e30–8.CrossRefPubMed
27.
go back to reference Robertson CG, Kesselheim A. Blinding as a solution to bias: strengthening biomedical science, forensic science, and law. 1st ed. Boca Raton: Academic Press; 2016. Robertson CG, Kesselheim A. Blinding as a solution to bias: strengthening biomedical science, forensic science, and law. 1st ed. Boca Raton: Academic Press; 2016.
28.
go back to reference Broeck JVD, Brestoff JR. Epidemiology principles and pracical guidelines. Dordrecht: Springer; 2013.CrossRef Broeck JVD, Brestoff JR. Epidemiology principles and pracical guidelines. Dordrecht: Springer; 2013.CrossRef
Metadata
Title
Point prevalence of SARS-CoV-2 infection in Sweden at six time points during 2020
Authors
Ramona Groenheit
Jessica Beser
Sharon Kühlmann Berenzon
Ilias Galanis
Edward van Straten
Jan Duracz
Marie Rapp
Disa Hansson
Mikael Mansjö
Sandra Söderholm
Shaman Muradrasoli
Anna Risberg
Richard Ölund
Andreas Wiklund
Kristoffer Metzkes
Matilda Lundberg
Philip Bacchus
Karin Tegmark Wisell
Andreas Bråve
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2022
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07858-6

Other articles of this Issue 1/2022

BMC Infectious Diseases 1/2022 Go to the issue